{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:16:37Z","timestamp":1684469797449},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,3,20]],"date-time":"2007-03-20T00:00:00Z","timestamp":1174348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1038\/ncponc0789","type":"journal-article","created":{"date-parts":[[2007,3,20]],"date-time":"2007-03-20T15:19:20Z","timestamp":1174403960000},"page":"276-277","source":"Crossref","is-referenced-by-count":0,"title":["Is bortezomib active in patients with mantle cell lymphoma?"],"prefix":"10.1038","volume":"4","author":[{"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,3,20]]},"reference":[{"issue":"Suppl 4","key":"BFncponc0789_CR1","doi-asserted-by":"publisher","first-page":"iv12","DOI":"10.1093\/annonc\/mdj992","volume":"17","author":"AD Zelenetz","year":"2006","unstructured":"Zelenetz AD (2006) Mantle cell lymphoma: an update on management. Ann Oncol 17 (Suppl 4): iv12\u2013iv14","journal-title":"Ann Oncol"},{"key":"BFncponc0789_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdl316","volume":"18","author":"A Belch","year":"2006","unstructured":"Belch A et al. (2006) A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 18: 116\u2013121","journal-title":"Ann Oncol"},{"key":"BFncponc0789_CR3","doi-asserted-by":"crossref","first-page":"a2049","DOI":"10.1182\/blood.V108.11.2049.2049","volume":"108","author":"RJ deLeeuw","year":"2006","unstructured":"deLeeuw RJ et al. (2006) Clinicopathologic subtypes of mantle cell lymphoma (MCL) show distinct patterns of genetic copy number alteration [abstract]. Blood 108: a2049","journal-title":"Blood"},{"key":"BFncponc0789_CR4","doi-asserted-by":"crossref","first-page":"a2753","DOI":"10.1182\/blood.V108.11.2753.2753","volume":"108","author":"J Drach","year":"2006","unstructured":"Drach J et al. (2006) Marked activity of bortezomib, rituximab, and dexamethasone in relapsed and refractory mantle cell lymphoma [abstract]. Blood 108: a2753","journal-title":"Blood"},{"key":"BFncponc0789_CR5","unstructured":"Richardson P : New drugs for myeloma. Oncologist, in press"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc0789.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0789","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0789.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:46:32Z","timestamp":1684442792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,20]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["BFncponc0789"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0789","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,20]]}}}